Background: Although regulatory T cells (Treg) are highly enriched in human tumours compared with peripheral blood, expression of the immune-checkpoint receptors, immunosuppressive molecules and function of Treg in these two sites remains undefined.
The frequency and function of regulatory T cells (Treg) are elevated in the peripheral blood and at the tumour sites of patients with cancers including head and neck squamous cell carcinoma (HNSCC; Ichihara et al, 2003; Schaefer et al, 2005; Hiraoka et al, 2006) . This enrichment of Treg in tumour-infiltrating lymphocytes (TIL) might be responsible for suppressing anti-tumour immunity in the tumour microenvironment (TME). Mechanisms underlying Treg accumulation at tumour sites are not clear. It has been suggested that enrichment of Treg in tumours could be induced by the conversion of FOXP3 À T cells into FOXP3 þ T cells in the presence of TGF-b1 and retinoic acid (Coombes et al, 2007; Sun et al, 2007) . Alternatively, peripheral Treg might be recruited into tumour sites and expanded as a result of specific self-antigen recognition by memory Treg (Darrasse-Jeze et al, 2009 ). This alternative implies that Treg activation and expansion takes place in the TME. Although these studies demonstrate that TCR triggering is a central event to Treg induction and expansion in the TME, molecules that contribute to the expansion and suppressive function of Treg remain largely unidentified.
Immune-checkpoint receptors (ICRs) including cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death-1 (PD-1), T-cell immunoglobulin and mucin protein-3 (TIM-3) and lymphocyte activation gene-3 (LAG-3) have been proposed as key molecules involved in generation and/or suppressive functions of Treg (Fife and Bluestone, 2008; Francisco et al, 2010; Joller et al, 2012; Pardoll, 2012) . In both mice and human, blockade of CTLA-4 abrogated immunosuppressive activity of Treg and enhanced effector T-cell functions (Tang et al, 2004; Zheng et al, 2008) . A recent study using PD-1-deficient mice suggested that PD-1 is involved in the development of inducible Treg but not in their immunosuppressive functions (Qiao et al, 2012) . In addition to the ICRs, Treg also express ectonucleotidases, CD39 and CD73, which have been proposed as immunosuppression-inducing molecules on Treg (Mandapathil et al, 2010) . CD39 converts ATP and ADP into cAMP, which is further converted into adenosine, a potent immunosuppressive agent, by CD73 (Bastid et al, 2013) . In addition to blocking lymphocyte functions, adenosine exerts immunosuppressive activity on macrophages and DCs and may promote tumour development by inhibiting innate immune responses, including phagocytosis and antigen presentation, and by secreting VEGF, TGF-b and IL-6 (Bastid et al, 2013) . Despite the potential importance of ICRs and CD39/CD73 molecules in the development and immunosuppressive functions of Treg, a comparative analysis of these molecules on Treg in the blood and tumour sites has not been performed.
In this study, we investigated the expression levels of ICRs and other immunosuppressive molecules on Treg isolated from tumour sites and peripheral circulation of head and neck cancer (HNC) patients. Using paired autologous TIL and peripheral blood lymphocyte (PBL) specimens, we observed that intratumoral Treg were more immunosuppressive than circulating Treg and suggest that elevated expression of ICRs on TIL may contribute to their expansion and/or suppressive activity in the TME.
MATERIALS AND METHODS
Patients and specimens. Peripheral venous blood samples and tumours were obtained from 27 patients with HNSCC as a baseline. All patients were seen in the Department of Otolaryngology at the University of Pittsburgh Medical Center. All subjects signed written informed consent approved by the Institutional Review Board of the University of Pittsburgh (IRB no. 99-06). The patient cohort included 10 females and 15 males with a mean age of 64.7 ± 9.9 years (range: 40-83 years) and the tumours were isolated from different sites as described in Table 1 .
Collection of PBMC and TIL. Blood samples from cancer patients and healthy donors (30-40 ml) were drawn into heparinized tubes and centrifuged on Ficoll-Hypaque gradients (GE Healthcare Bioscience, Piscataway, NJ, USA). Peripheral blood mononuclear cells (PBMC) were recovered, washed in RPMI-1640 or AIM-V medium (Invitrogen, Carlsbad, CA, USA) and immediately used for experiments. For TIL isolation, freshly isolated tumours from HNC patients were minced into small pieces, which then were transferred to a cell strainer (70 mm Nylon) and mechanically separated by using a syringe plunge. The cells passing through the cell strainer were collected and subjected to Ficoll-Hypaque gradient centrifugation. After centrifugation, mononuclear cells were recovered and stored at À 80 1C until flow cytometry analysis.
Antibodies and reagents. The following anti-human monoclonal antibodies (mAb) were used for staining: CD39-FITC/ PC7, FOXP3-FITC (clone PCH101), LAP-PE, PD-1-APC (all eBioscience, San Diego, CA, USA), CD73-PE, CTLA-4-PE, TIM-3-Brillian violet 421, CD25-PE-Cy7, Ganzyme B-FITC, Perforin-APC, CD39-APC, CD86-PE (all Biolegend, San Diego, CA, USA), LAG-3-ATTO647N conjugate (Enzo Life Sciences, Farmingdale, NY, USA), CD4-PE-Texas Red, CD3-Alexa Fluor 405 conjugate (Invitrogen) and CD4-AF700, CD80-FITC, HLA-DR-APC (all BD Biosciences, San Jose, CA, USA) including their respective isotypes, which served as negative controls for surface as well as intracellular staining. All Abs were pre-titrated using activated as well as nonactivated PBMC to determine optimal staining dilutions.
Flow cytometry. For cell surface staining, PBMCs and TIL were washed twice in staining buffer (2% w/v fetal bovine serum) and stained for cell surface markers as described (Lopez-Albaitero et al, 2009) . Briefly, cells were incubated with relevant Abs for 20 min at room temperature (RT) in the dark, washed twice and re-suspended in staining buffer. Intracellular staining for FOXP3 was performed according to the manufacturer's protocol (eBioscience). Briefly, PBMCs or TIL were stained with mAb for surface markers, washed and subsequently fixed and permeabilized by using Fix/Perm buffer. After washing, cells were stained for their intracellular FOXP3. Flow cytometry was performed using a CyAn flow cytometer (Dako, Ft. Collins, CO, USA), or Fortesa cytometry (Becton Dickinson, Franklin Lakes, NJ, USA) and data analysed using Summit V4.3 software or flowJo software (TreeStar, Inc., Ashland, OR, USA). The acquisition and analysis gates were restricted to the lymphocyte gate based on characteristic properties of the cells in the forward and side scatter. At least 1 Â 10 5 events were acquired for analysis and, where applicable, gates were restricted to the CD3 þ CD4 þ subset for Treg analysis.
Treg suppression assays. The CD4 þ CD25 þ T cells were enriched from TIL or PBL using human CD4 þ CD25 þ Treg isolation kit (STEMCELL Technologies, Vancouver, BC, Canada) and tested for their immunosuppressive activity in co-culture with autologous CD4 þ CD25 À responder cells (RC) in the presence of CD14 þ antigen-presenting cells (APCs), which is slightly modified from the previously described method (Strauss et al, 2007) . CFSElabelled autologous CD4 þ CD25 À cells (4 Â 10 4 cells/well) were incubated in wells of round-bottom 96-well plates at RC to Treg ratio of 1 : 1, 1 : 0.5, 1 : 0.25 and 1 : 0. To induce proliferation, RC were stimulated with soluble OKT3 (anti-human CD3, 10 mg/ml) in the presence of autologous CD14 þ APC for 4 days. All CFSE data were collected by a Fortesa cytometry (Becton Dickinson) and analysed using the flowJo software (TreeStar, Inc.). The percentages of suppression were calculated based on the proliferation index (PI) of RCs alone compared with the PI of cultures containing responders and Treg. The program determines the per cent of cells within each peak, and the sum of all peaks in the control culture is taken as 100% of proliferation and 0% of suppression.
Statistical analysis. Averages were calculated as means. For nonparametric distribution of samples, P-values were calculated by Wilcoxon-matched pair test or Mann-Whitney test using GraphPad Prism. P-valueso0.05 were considered to be significant. Figure 1A , CTLA-4, P ¼ 0.002; TIM-3, P ¼ 0.002 and PD-1, P ¼ 0.002). CTLA-4 and TIM-3 were preferentially expressed by FOXP3 þ CD25 hi CD4 þ TIL and PBL, defining a distinct subset of Treg. Although PD-1 was predominantly expressed by the CD4 þ CD25 hi T subset compared with CD4 þ CD25 med and CD4 þ CD25 neg T-cell subsets, it was also expressed by some FOXP3-negative cells regardless of CD25 expression (Supplementary Figure 1A) . Therefore, PD-1 was not a specific biomarker for intratumoral CD25 hi FOXP3 þ Treg. For LAG-3, no significant expression was found among CD4 þ TIL subsets, but LAG-3 was predominantly expressed by CD4 þ CD25 hi PBL subsets (Supplementary Figure 1B) , consistent with previous report that LAG-3 predominates on CD4 þ CD25 hi FOXP3 þ Treg in PBL (Camisaschi et al, 2010) . Taken together, these results indicate that the frequency of cells expressing immune-checkpoint receptors, including CTLA-4, TIM-3 and PD-1, is significantly increased on intratumoral FOXP3 þ CD25 hi Treg compared with circulating Treg.
CD39 and LAP are predominantly upregulated by intratumoral CD4 þ FOXP3 þ Treg. As concordant expression of the adenosine pathway ectoenzymes CD39 and CD73, has been strongly associated with human inducible FOXP3 þ Treg (Mandapathil et al, 2010 , Schuler et al, 2012 , we investigated whether there is differential expression of these molecules between intratumoral FOXP3 þ Treg and circulating Treg. To do this, CD4 þ T cells in PBL and TIL were divided into FOXP3 þ and FOXP3 À cells to examine the correlation between CD39/CD73 and FOXP3 expression. Interestingly, the frequency of CD39 þ cells was higher among intratumoral FOXP3 þ CD4 þ T cells compared with circulating FOXP3 þ CD4 þ T cells (Figures 2A, P ¼ 0.004 ). In addition, CD39 expression levels (mean fluorescent intensity, MFI) were also significantly higher in FOXP3 þ CD4 þ TIL than in circulating FOXP3 þ CD4 þ PBL ( Figures 2B, P ¼ 0.002 ). However, no significant difference in the frequency of CD73 þ cells was detected between FOXP3 þ and FOXP3 À CD4 þ T cells in both TIL and PBL (Supplementary Figure 2) . The frequency of CD73 þ cells in some intratumoral FOXP3 þ CD4 þ T cells was higher than that in circulating FOXP3 À CD4 þ T cells. Although CD39 expression was found on both FOXP3 þ and FOXP3 À CD4 þ T cells, the fraction of CD39 þ cells was disproportionately higher on FOXP3 þ CD4 þ T cells in TIL and PBL than FOXP3 À CD4 þ T cells ( Figure 2E ). Analysis of LAP (membrane-bound active form of TGF-b) expression on CD4 þ T cells showed that both frequency and expression of LAP þ cells were significantly higher on FOXP3 þ CD4 þ TIL than circulating FOXP3 þ CD4 þ PBL (Figures 2C and D, P ¼ 0.002). In addition, the fraction of LAP þ cells was significantly higher on FOXP3 þ CD4 þ T cells than FOXP3 À CD4 þ T cells in both TIL and PBL ( Figure 2F ). Together, these observations suggest that both immunosuppressive molecules, CD39 and LAP, are more robustly expressed by intratumoral with those of FOXP3 À CD4 þ TIL to identify molecules that best characterise intratumoral FOXP3 þ Treg. We found that the majority of intratumoral CD4 þ FOXP3 þ Treg (480%) concomitantly expressed CTLA-4 and CD39, and only about half co-expressed CD39 and TIM-3 ( Figure 3 ). However, these highly co-expressed CTLA-4 and CD39 molecules were not found in FOXP3 À CD4 þ TIL. In addition, FOXP3 À CD4 þ TIL expressed relatively high level of CD39 on their surface, compared with relatively poorly expressed CTLA-4 and TIM-3 molecules ( Figure 3A) .
The intratumoral FOXP3 þ Treg are more suppressive than circulating FOXP3 þ Treg. As intratumoral Treg exhibited more immunosuppressive phenotypes than circulating Treg, we determined whether they are functionally more suppressive than the peripheral blood Treg. To do this, we enriched CD4 þ CD25 þ T cells from TIL and PBL isolated from two patients and performed Treg suppressive assay to compare their suppressive activity. We designated these cells as TIL-Treg and PBL-Treg, respectively. As shown in Figure 4 , TIL-Treg were more potently suppressive in regulating T-cell proliferation than PBL-Treg in both patients. In patient no. 01, TIL-Treg potently suppressed autologous CD4 þ T-cell proliferation (CFSE low cells) even at 1 : 0.25, the ratio of Treg to RCs. Although PBL-Treg was as suppressive as TIL-Treg at 1 : 1 ratio of Treg to RC, they gradually lost their suppressive activity as the ratio decreased (1 : 0.5 and 1 : 0.25). In the case of patient no. 02, suppressive activity of TIL-Treg was more potent than that of PBL-Treg at all the ratio of Treg to RC. This result strongly suggests that intratumoral Treg are functionally more suppressive than circulating Treg, which also indicates that immunosuppressive phenotype of TIL-Treg is positively correlated with their suppressive function.
DISCUSSION
In this study, we demonstrated that the frequency of not only immune-checkpoint receptors, including CTLA-4 þ , TIM-3 þ and PD-1 þ cells, but also immune suppressive molecules, such as CD39 þ and TGF-b1 þ cells, were significantly increased on intratumoral Treg compared with circulating Treg. Particularly, we found that CTLA-4 and CD39 were co-expressed on the majority of intratumoral Treg, which suggests that the blockade of CTLA-4 or CD39 enzymatic activity might enhance anti-tumour immunity in the TME by inhibiting immunosuppressive activities of intratumoral Treg. We also observed that intratumoral Treg exhibited more suppressive activity than peripheral blood Treg. Taken together, this study provides insight into mechanisms and markers of intratumoral Treg, which are potently immunosuppressive cells. These CTLA-4 þ /CD39 þ Treg are major targets to inhibit their suppressive function, thus promoting anti-tumour immunity in the TME. Many studies define CTLA-4 as an effector receptor in mediating Treg immunosuppressive functions (Walker and Sansom, 2011) . For example, the FOXP3 þ Treg-specific loss of CTLA-4 is sufficient to induce fatal lymphoproliferative disease, which is similar to that observed in CTLA-4-deficient mice (Wing et al, 2008) . It has also been reported that Treg can induce indoleamine 2,3-dioxygenase (IDO) activity in APCs through CTLA-4 and CD80/CD86 interaction. Indoleamine 2,3-dioxygenase catabolizes tryptophan, depleting its local supply to immune cells and subsequently inhibiting effector T-and NK-cell functions (Pietra et al, 2012) . Similarly, it has been suggested that antibodytriggering of CTLA-4 can induce the release of TGFb1 from Treg (Oida et al, 2006) . However, the link between CTLA-4 and IDO/ TGFb1 currently remains controversial, albeit their critical roles in Treg-mediated immune suppressive activities have been recognised (Walker and Sansom, 2011) . Ectonucleotidases, CD39 and CD73, have been proposed as important contributors to Treg-mediated immunosuppressive functions, thereby promoting tumour progression (Bastid et al, 2013) . One recent study demonstrated that anti-CD39 specific blocking mAb attenuated immunosuppressive functions of Treg and restored CD4 þ and CD8 þ T cells (Nikolova et al, 2011 ), suggesting a potential role for CD39 in regulating T-cell-mediated antitumour immunity. Although it has been well known that intratumoral Treg are strongly immunosuppressive, the molecules mediating immunosuppressive activities have not been thoroughly investigated in paired intratumoral Treg and circulating Treg. We observed that CTLA-4, CD39 and TGFb1 molecules are predominantly expressed by intratumoral FOXP3 þ Treg compared with circulating Treg (Figures 1 and 2) , suggesting that these molecules may be involved in enhancing immune suppressive activities of Treg in TME. Particularly, we observed that CD39 and CTLA-4 were co-expressed on the majority of intratumoral Treg, suggesting that these two molecules may be key modulators of functional FOXP3 þ Treg in the TME. Therefore, these results indicate that the blockade of CTLA-4, TGFb1 or CD39 on Treg may facilitate anti-tumour immunity by enhancing functional activation of immune cells such as DC, T and NK cells in the TME.
Although several studies of human cancer indicate that intratumoral FOXP3 þ Treg may be associated with poor prognosis (deLeeuw et al, 2008) , little information is available regarding the mechanisms underlying the enrichment of Treg in the TME. One study showed that FOXP3 þ Treg are rapidly recruited into tumour sites and expanded as a consequence of triggering through self-antigen reactive TCR (Darrasse-Jeze et al, 2009) . A recent report analysing the T-cell receptor (TCR) repertoire of intratumoral Treg suggested that a few dominant Treg clones containing the so-called public TCR sequences were markedly expanded through TCR responses in the TME (Sainz- Perez et al, 2012) . However, the mechanism underlying the expansion of Treg at the tumour sites has not been thoroughly investigated in these studies. Further, it has been reported that CTLA-4 interacts with CD80 with affinity, which is more than 20 times stronger than that for CD86 (Walker and Sansom, 2011) . Also, it has been proposed that the preferential engagement of CTLA-4 by CD80 during antigen presentation is one of the critical events allowing for the contact between DC and Treg, thus leading to expansion of Treg (Perez et al, 2008) . In this respect, during antigen presentation in the TME, Treg preferentially interact with intratumoral APCs through strong CTLA-4-CD80 interaction, which may affect not only expansion of Treg but also their potently immunosuppressive functions at tumour sites. Given that the interaction between Treg and APCs is one of the critical events to determine the expansion and suppressive functions of Treg, it is important area to investigate the molecules that mediate this cellular interaction to understand the mechanism whereby relatively more enriched and immunosuppressive Treg are induced in the TME. For example, interaction between PD-1 on T cells and PD-L1 on APCs regulates the development, maintenance and function of induced Treg (Francisco et al, 2009 ). Therefore, it would be interesting to identify the molecules mediating this interaction between Treg and APCs to gain better understanding the mechanism by which enhanced frequency and functions of Treg are consistently induced, thus maintaining potent immunosuppressive microenvironment at cancer patients' tumour sites.
Treg: RC ratio 1:1 0.5:1 0.25: by CD25 þ CD4 þ T cells isolated from TIL or PBL (from two patients). CFSE-labelled CD4 þ CD25 À T cells were co-cultured with unlabelled autologous CD4 þ CD25 þ T cells isolated from TIL or PBL as indicated. After 4 days of stimulation with anti-CD3 antibody, CFSE þ CD4 þ T cells were analysed for their proliferation by CFSE dilution. (B) Percentage of suppression of TIL-Treg was compared with that of PBL-Treg from two patients, respectively.
